Author: VANDA PHARMACEUTICALS INC

Posted Date:

April 9, 2026

Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines

VANDA PHARMACEUTICALS INC

April 9, 2026
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists

VANDA PHARMACEUTICALS INC

April 8, 2026
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years

VANDA PHARMACEUTICALS INC

March 3, 2026
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference

VANDA PHARMACEUTICALS INC

February 26, 2026
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

VANDA PHARMACEUTICALS INC

February 25, 2026
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia – A New Chemical Entity Opening New Horizons in Psychiatric Innovation

VANDA PHARMACEUTICALS INC

February 20, 2026
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

VANDA PHARMACEUTICALS INC

February 12, 2026
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

VANDA PHARMACEUTICALS INC

February 8, 2026